Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
Clinical Breakthroughs

New Therapy Reduces Symptoms of Inherited Enzyme Deficiency

By Sarah PlumridgeOct 9, 2015
Share
Facebook Twitter Email
burtonbarbara
Barbara Burton, ’73 MD, ’75 ’77 GME, professor of Pediatrics in the Division of Genetics, Birth Defects and Metabolism, led a phase three clinical trial that evaluated the effectiveness and safety of a new enzyme replacement therapy for patients with lysosomal acid lipase deficiency.

A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.

Barbara Burton, ’73 MD, ’75 ’77 GME, professor of Pediatrics in the Division of Genetics, Birth Defects and Metabolism, was the principal investigator for this study, recently published in The New England Journal of Medicine.

Currently, there are no safe or effective therapies for lysosomal acid lipase deficiency. Cholesterol-lowering medications have had limited success in reducing the progression of the disease and the eventual need for liver transplant.

A total of 66 patients were enrolled in the multi-center study, which was designed and supported by Synageva BioPharma, the pharmaceutical company that manufactures the drug. Patients were randomly assigned to receive either sebelipase alfa or a placebo for 20 weeks before entering the open-label period. The investigators evaluated the effectiveness of the therapy through the normalization of the alanine aminotransferase level (ALT), a test used to detect liver damage. They also looked at other disease-related symptoms and possible side effects.

“The enzyme replacement therapy appears to be effective in clearing fat from the liver of patients with this deficiency and normalizing their ALT,” said Dr. Burton, also a member of the Center for Genetic Medicine and the Stanley Manne Children’s Research Institute at the Ann & Robert H. Lurie Children’s Hospital of Chicago. “In many cases, we are hopeful this will prevent progression of the disease by reducing fat accumulation in the liver and prevent the need for liver transplantation.”

The clinical trial reported at 20 weeks that the ALT level was normal in 31 percent of patients in the sebelipase alfa group, and they observed improvements in lipid levels and reduction of fat content in the liver.

Dr. Burton is working on another clinical trial to evaluate this therapy in patients with more advanced disease.

Genetics Pediatrics Research
Share. Facebook Twitter Email

Related Posts

Largest cell map of human lung reveals insights into disease

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023

Developing New Nanoparticle Treatments for Brain Tumors

Jun 6, 2023

Comments are closed.

Latest News

Largest cell map of human lung reveals insights into disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023

Developing New Nanoparticle Treatments for Brain Tumors

Jun 6, 2023

Newly Discovered Mechanisms Increase Chemotherapy Resistance in Breast Cancer 

Jun 5, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.